North America Uterine Cancer Diagnostics & Treatment Market - Growth, Trends, and Forecast (2019-2024)

The market is segmented by Cancer Type (Endometrial Cancer, Uterine Sarcoma), Procedure, and Geography.

Market Snapshot

Picture1
Study Period:

2016-2024

Base Year:

2018

CAGR:

4.92%

Key Players:

Looking to buy specific charts and data points? Access the full report online to choose the data you want.

Market Overview

Uterine cancer is one such cancer that presently shows an increasing incidence and mortality in the United States. In North America, healthcare providers and community programs help women achieve and maintain a healthy weight and get enough physical activity, which can reduce the risk for endometrial cancer, the most common uterine cancer. Promoting awareness of the need for timely evaluation of abnormal vaginal bleeding (between periods, after sex, or after menopause), an important symptom of uterine cancer increases the chance for early detection and treatment.

Recent breakthroughs have led to many advances in personalized approaches to various cancer types, including cancers of the female reproductive system, like uterine cancer and endometrial cancer. Across entire North America, especially in the United States, in all the healthcare organizations, gynecologic oncologists are available to provide the common people with a second opinion and design a treatment plan tailored to the tumor type, cancer stage, and individual needs. Such initiatives have a positive impact on the uterine cancer treatment and diagnostics market in North America.

Scope of the Report

Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. Risk factors associated with this cancer are being overweight and starting periods at an early age.

By Cancer Type
Endometrial Cancer
Uterine Sarcoma
By Procedure
Treatment
Surgery
Immunotherapy
Radiation Therapy
Chemotherapy
Other Treatments
Diagnostics
Biopsy
Ultrasound
Hysteroscopy
Dilation and Curettage
Other Diagnostics
Geography
North America
US
Canada
Mexico

Report scope can be customized per your requirements. Click here.

Key Market Trends

Immunotherapy to Register Highest CAGR Over the Forecast Period

Immunotherapy is a type of treatment, in which drugs help an individual’s immune system to recognize the cancer cells and kill them. Immunotherapy is done for treating certain forms of endometrial cancer that has spread or recurred. Pembrolizumab (Keytruda) by Merck and Co. is a drug that is used for the immunotherapy. This drug had got the FDA approval in June 2018, and it is currently available in the market. This drug is given as an intravenous (IV) infusion every 3 weeks. Currently, there are several ongoing clinical trials meant for examining different drugs and their combinations in uterine cancer, including a combination of two immunotherapies, such as lenvatinib (Lenvima) and pembrolizumab.

Some types of immunotherapy include monoclonal antibodies and tumor-agnostic therapies, non-specific immunotherapies, oncolytic virus therapy, T-cell therapy, and cancer vaccines. However, among these types, only tumor-agnostic therapy is used. As the number of uterine cancer cases is increasing, companies are focusing more on producing novel drugs for immunotherapy. Therefore, it is expected that the use of immunotherapy may grow in the coming future. Thus, this may positively affect the overall market for uterine cancer treatment.

Picture2

To understand key trends, access the platform now

Competitive Landscape

The uterine cancer diagnostics and treatment market is comprised of the global players that are having a focus on oncology division. Some of the major companies in this market include Merck & Co. Ltd, Pfizer Inc.,  AbbVie Inc., among others. With the rising research by pharmaceutical industry on the development of better therapeutics and diagnostics for various cancers, more companies are believed to enter the market in the coming future.

Major Players

  1. AbbVie Inc.
  2. Merck & Co. Ltd
  3. Pfizer Inc.
  4. Becton Dickinson and Company
  5. Bristol-Myers Squibb Company

* Complete list of players covered available in the table of contents below

Picture4

Buy specific charts and data points from as low as 25$.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Awareness about Uterine Diseases and the Available Therapies

      2. 4.2.2 Increasing Health Care Expenditure

      3. 4.2.3 Innovation in Drug Development and Subsequent Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs and High Cost of Research and Development

      2. 4.3.2 High Cost Associated with the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Endometrial Cancer

      2. 5.1.2 Uterine Sarcoma

    2. 5.2 By Procedure

      1. 5.2.1 Treatment

        1. 5.2.1.1 Surgery

        2. 5.2.1.2 Immunotherapy

        3. 5.2.1.3 Radiation Therapy

        4. 5.2.1.4 Chemotherapy

        5. 5.2.1.5 Other Treatments

      2. 5.2.2 Diagnostics

        1. 5.2.2.1 Biopsy

        2. 5.2.2.2 Ultrasound

        3. 5.2.2.3 Hysteroscopy

        4. 5.2.2.4 Dilation and Curettage

        5. 5.2.2.5 Other Diagnostics

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 US

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Becton, Dickinson and Company

      3. 6.1.3 Bristol-Myers Squibb Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Merck & Co. Inc.

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Takeda Pharmaceutical Company Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information